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SHORT COMUNICATION
COPD, stage and treatment in a large outpatient clinic
Claire Præst Holma, Jakob Holmb, Annette Nørgaardc and Nina Godtfredsena
aDepartment of Respiratory Medicine, Copenhagen University Hospital, Hvidovre, Denmark; bDepartment of Endocrinology, Copenhagen
University Hospital, Hvidovre, Denmark; cLunge- og allergiklinikken, Hellerup, Denmark
ABSTRACT
Some COPD patients suffer from frequent exacerbations despite triple inhalation treatment.
These frequent exacerbators should be identified, as exacerbations often lead to decreasing
lung function and increasing mortality. Roflumilast reduces exacerbations in patients with a
previous history of exacerbations. Our aim was to describe COPD patient characteristics and
compare roflumilast treatment eligible to non-eligible patients. An observational cross-section
study was conducted. Patients were included from a large COPD outpatient clinic. Information
regarding COPD patient characteristics was registered on a standardized form and lung function
was measured. Patients were categorized according to the GOLD classification. Eligibility for
roflumilast treatment was assessed and patient characteristics compared between groups. 547
patients were included. Most patients (54%) were in GOLD group D. 62 patients (11.3%) met the
criteria for treatment with roflumilast. Among the patients eligible for roflumilast treatment, only
14 patients (22.6%) were receiving treatment. There were no significant differences in FEV1,
number of exacerbations, hospitalization due to exacerbation, MRC grade, age, smoking status
and medication use between patients receiving roflumilast and not treated eligible patients. Our
study documents low use of roflumilast treatment. In view of the established effect of roflumilast
we think that this treatment should be considered more consistently as an option among COPD
patients fulfilling the criteria for this therapy.
ARTICLE HISTORY
Received 23 March 2016
Accepted 29 November 2016
KEYWORDS
COPD; exacerbations;
roflumilast;
phosphodiesterase-4
inhibitor; GOLD groups;
outpatients; frequent
exacerbator
Introduction
Some chronic obstructive pulmonary disease (COPD)
patients suffer from frequent exacerbations despite tri-
ple-treatment with inhaled corticosteroids (ICS), long-
acting β2-agonists (LABA) and long-acting muscarinic
antagonists (LAMA). As a history of previous exacerba-
tions [1] has been found to be the best predictor of future
exacerbations, early identification of these patients is
important in order to optimize individual treatment.
Recently, phenotypical categorization of COPD patients
based on clinical features has become more widespread.
This categorization might have the possibility of enabling
more individualized, pharmacological treatment. The
Evaluation of COPD Longitudinally to Identify
Predictive Surrogate Endpoints (ECLIPSE) study identi-
fied different COPD phenotypes including the ‘frequent
exacerbator’.[1] Exacerbations are known to have a detri-
mental effect on patient-related outcomes, often leading
to decreasing lung function [2] and increasing mortality.
[3] Furthermore, patients with frequent exacerbations are
found to have a reduced response to therapy and a higher
level of inflammatory serum markers as compared to
other phenotypes.[4] This persistent inflammation has
been proposed as an explanation of the reduced lung
function observed in these patients.[4]
Roflumilast is an oral phosphodiesterase-4 (PDE-4)
inhibitor that reduces inflammation [5] and reduces
exacerbations in patients with COPD. It is approved
for the treatment of COPD in patients with forced
expiratory volume in 1 s (FEV1) of ≤ 50% predicted,
chronic bronchitis and a history of at least two exacer-
bations in the previous year.[6] The expenses for the
drug can only be reimbursed if the patients fulfil all of
the above criteria.
The present study was conducted in one of Denmark’s
largest COPD outpatient clinics, Copenhagen University
Hospital, Hvidovre. Our aim was to describe patient char-
acteristics in terms of lung function, presence of chronic
bronchitis, treatment and exacerbations in a large cohort of
COPD-patients. Prevalence of COPD according to The
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) groups A–D was assessed. Furthermore, preva-
lence of treatment with roflumilast in patients eligible for
this medication was investigated.
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Methods
The study was an observational cross-section study.
Patients were included in a six-month period from 1
January to 30 June 2015. All patients with a diagnosis
of COPD seen by a physician in the outpatient clinic
situated at the Copenhagen University Hospital,
Hvidovre were eligible to participate in the study. If
patients had more than one visit during the inclusion
period only results from the last visit were included in
the analysis. There were no further inclusion or exclu-
sion criteria. Information regarding lung function,
degree of dyspnea, smoking habits, exacerbations the
previous year and hospitalization for these, and pre-
sence of chronic bronchitis was collected and registered
on a standardized form (Figure 1). COPD specific
medication status and possible change in medical treat-
ment at the current visit was registered. Patients were
subsequently categorized according to the GOLD
groups A–D and determination of eligibility for treat-
ment with roflumilast was registered.
The degree of dyspnea was determined according to
the Medical Research Council Questionnaire (MRC).
Chronic bronchitis was defined as coughing and sputum
on most days for ≥ 3 consecutive months for at least two
consecutive years.[7] Exacerbations were registered as 0,
1, 2, 3 or ≥ 4 the previous year and defined as episodes
of worsening requiring treatment with prednisolone
and/or antibiotics or hospital admission. Use of COPD
related medication was recorded as current use of short-
acting β2-agonists (SABA)/short-acting muscarinic
antagonists (SAMA), LAMA, LABA, ICS, prednisolone
and/or antibiotics for acute exacerbation or other treat-
ment. Finally, former and present use of roflumilast was
registered. Prescription of roflumilast is exclusively per-
formed by respiratory specialists (or after conferral with
such) and are in accordance with guidelines from the
Danish Medicines Agency. Spirometry was performed
using Spirotrac® manufactured by Spiropharma. The
spirometers were calibrated every morning.
Statistical analysis was conducted using SAS version
9.4. Baseline characteristics are presented as numbers
and percentages of observations for categorical vari-
ables. Continuous variables are presented with means
or medians with corresponding standard deviations or
inter quartile range. Comparisons between groups were
performed using unpaired two-sample t-test, Wilcoxon
two sample t-test, Fisher’s exact test or χ2-test as appro-
priate. In case of unequal variances, unequal variances
t-test was used instead of the regular t-test. Significance
was defined as a two-sided p-value ˂ 0.05.
The project was approved by the relevant Danish
authorities including the Danish data protection
agency.
All patients provided written informed consent
before inclusion in the study.
Results
During the six-month inclusion period 580 forms with
written consent were collected. Of those, 33 had filled
forms on two separate occasions. This led to 547
patients being included in the study.
Most patients (n = 296) were in GOLD group D, but
there was also a large proportion (n = 95) in GOLD
group A (Table 1). The mean prevalence of exacerba-
tions was 1, and 28% of the patients had been hospita-
lized due to an exacerbation. The distribution
according to the number of exacerbations is shown in
Figure 2.
Mean FEV1 was 45.5% and the prevalence of
chronic bronchitis was 50%. More than 80% of the
patients received inhalation therapy with LABA,
LAMA and SABA/SAMA, and ICS was taken by 69%.
Of other medication azithromycin was recorded in
1.3% of the total population (Table 1).
Sixty-two patients (11.3%) met the criteria for treat-
ment with roflumilast. These patients had a significantly
lower lung function (mean FEV1 was 13.3% lower in the
•FEV
1
% of expected
•Tiffenau index
•MRC grade
•Exacerbations the 
previous year
•Hospitalization due 
to exacerbation
•Chronic bronchitis
•Smoking status
Nurse
•COPD medication status
Physician
• GOLD group
• Eligibility to Roflumilast    
treatment 
Investigator
Figure 1. Summary of collection of data. Abbreviations: FEV1, forced expiratory volume; MRC-grade, Medical Research Council
questionnaire; GOLD, the Global Initiative for Chronic Obstructive Lung Disease.
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‘eligible for roflumilast group’ (p ˂ 0.001)). The MRC
grade was significantly higher (p ˂ 0.001) and, as
expected, exacerbations were more frequent (p ˂ 0.001)
in the patients eligible for roflumilast treatment. A higher
percentage of these patients had been hospitalized for an
exacerbation (54.8% against 24.2%, p ˂ 0.001). There was
no significant difference in gender (p = 0.87), proportion
of smokers (p = 0.25) or in age (p = 0.44) between groups.
Among the patients eligible for roflumilast treat-
ment, only 14 patients (22.6%) were receiving the treat-
ment. One patient had received the medication
previously but stopped due to side effects. Eight
patients had not taken roflumilast earlier but had it
prescribed during the present visit. All patients taking
roflumilast were already prescribed triple inhalation
therapy. There were no significant differences between
the patients receiving roflumilast and those who did
not (but were eligible to the therapy). FEV1, number of
exacerbations, hospitalization due to exacerbation,
MRC grade, age, smoking status and medication use
were the same in the two groups.
Discussion
We found that 54% of our cohort of patients seen at a
specialist COPD outpatient clinic were in GOLD group D.
We furthermore identified 11% of patients as eligible for
Table 1. Patient charecteristics.
All patients
(n = 547)
Patients not eligible for
roflumilast (n = 484)
Patients eligible for
roflumilast (n = 62)
Age, mean (SD) 68.9 (±10.5) 69.0 (±10.5) 67.9 (±9.9)
FEV1 % predicted, mean (SD) 45.5 (±16.3) 47.0 (±16.3) 33.7 (±10.7)
Female sex, n (%) 311 (57.0%) 275 (56.9%) 36 (58.1%)
MRC-grade, median (IQR) 3 (2;4) 3 (2;4) 4 (3;5)
Number of exacerbations, median (IQR) 1 (0;1) 0 (0;1) 3 (2;4)
Hospitalization due to exacerbation, n (%) 152 (27,8%) 117 (24,2%) 34 (54,8%)
Chronic bronchitis, n (%) 274 (50.6%) 212 (44.2%) 62 (100%)
Smokers, n (%) 138 (25.3%) 126 (26.1%) 12 (19.4%)
GOLD group A, n (%) 95 (17.4%) 95 (19.6%) 0
GOLD group B, n (%) 57 (10.4%) 57 (11.8%) 0
GOLD group C, n (%) 99 (18.1%) 92 (19%) 6 (9.7%)
GOLD group D, n (%) 296 (54.1%) 240 (49.6%) 56 (90.3%)
SABA/SAMA, n (%) 457 (83.6%) 398 (82.2%) 58 (93.6%)
LAMA, n (%) 454 (83%) 395 (81.6%) 58 (93.6%)
LABA, n (%) 482 (88.1%) 421 (87%) 60 (96.8%)
ICS, n (%) 378 (69.1%) 319 (65.9%) 58 (93.6%)
Roflumilast, n (%) 14 (2.6%) 0 14 (22.6%)
Previous roflumilast, n (%) 11 (2%) 4 (0.8%) 7 (11.3%)
Azithromycin, n (%) 7 (1.3%) 4 (0.8%) 3 (4.8%)
Antibiotics for acute exacerbation, n (%) 25 (4.6%) 18 (3.7%) 7 (11.3%)
Prednisolone for acute exacerbation, n (%) 27 (4.9%) 19 (3.9%) 8 (12.9%)
SD, standard deviation; IQR, inter quartile range; FEV1, forced expiratory volume; MRC-grade, MEDICAL RESEARCH COUNCIL
questionnaire; GOLD, the Global Initiative for Chronic Obstructive Lung Disease; SABA/SAMA, short-acting β2-agonists/short-
acting muscarinic antagonists; LAMA, long-acting muscarinic antagonists; LABA, long-acting β2-agonists; ICS, inhaled
corticosteroids.
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Figure 2. Distribution of the number of exacerbations in the previous year.
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roflumilast treatment. The proportion of eligible patients
who actually received treatment was low at 22,6%.
Surprisingly many patients were in GOLD group A.
A possible explanation for this could be that some of
these patients have asthma-COPD overlap syndrome
(ACOS) and are primarily seen at the clinic because of
their asthma. GOLD group A patients are supposed to
be followed by their general practitioner.
It was our experience that very few patients did
not want to participate in the study. In spite of this
some patients were not included. Only patients with
established COPD were included in the study. This
meant that some patients who had not yet been
formerly diagnosed with COPD (e.g. a diagnosis
was made during this particular visit), were not
included in the study. Some forms (approximately
25) had missing written consent although oral con-
sent had been given and were thus not included in
the study.
The REACT study showed that the number of
severe exacerbations, i.e. exacerbations leading to hos-
pitalization or death, were reduced by 24% in the
roflumilast group.[6] This effect was even more pro-
nounced in patients who had at least one hospitaliza-
tion due to exacerbation in the previous year. In that
case, severe exacerbations were reduced by 35%.[8]
Another study found that the re-hospitalization rate
in a 30-day period following hospitalization for
exacerbation was lower in the roflumilast group.[9]
More than half of our patients eligible for roflumilast
treatment had been hospitalized due to exacerbation
the previous year. It is well established that hospitali-
zation, especially re-hospitalization, increases mortal-
ity in COPD patients.[3] Wedzicha et al. [10] have
shown that roflumilast can shift patients from the
frequent exacerbator phenotype to the more stable
infrequent exacerbator phenotype.
We established that 62 (11%) of our patients were
eligible for roflumilast treatment, and only 22.6% of
these 62 actually received the treatment. To our
knowledge, the prevalence of actual treatment of
roflumilast eligible candidates has not been investi-
gated before. A possible explanation of the observed
low prevalence of roflumilast treatment in our study
could be that some physicians prefer azithromycin to
roflumilast for the frequent exacerbators. However,
since azithromycin was only used in three of these
patients (4.8%) this was not the case. Another expla-
nation could be that the patients had previously been
treated with roflumilast and had terminated the treat-
ment due to side effects. However, we did not find
evidence of this, as this was only the case for a single
patient. This was quite surprising in light of the pre-
valence of documented side effects in other studies.[6]
Another possibility could be that individual physi-
cians were reluctant to prescribe roflumilast due to
personal perceived or actual experience with side
effects of treatment in other patients. The rate of
side effects has shown to be even higher in a real-life
populations than in the pharmaceutical phase III trials
studies.[11] It is possible that knowledge hereof has
refrained some physicians from prescribing roflumi-
last to eligible patients. We did not include registra-
tion of body mass index (BMI) in our study, which
might have influenced the physicians’ choice of roflu-
milast, as weight loss has been shown to be a common
side effect.[6]
We found no differences in FEV1, number of
exacerbations or use of medication between patients
who were on roflumilast and those who were not (but
were eligible to the therapy). This suggests that initia-
tion of treatment was random and that, surprisingly, it
was not the patients with the most frequent exacerba-
tions or the lowest FEV1 who were started on
roflumilast.
Conclusion
Our study among 547 COPD patients from an out-
patient specialist clinic showed that only 54% of the
patients were in GOLD group D. Of the patient popu-
lation 11% was eligible for roflumilast treatment but
only 22.6% of these actually received the treatment.
The number of exacerbations and the FEV1 did not
predict prescription of roflumilast.
In view of our results documenting low use and the
established effect of roflumilast treatment, we think
that treatment with roflumilast should be considered
more consistently as an option among COPD patients
fulfilling the criteria for this therapy.
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